Venetoclax After TKI to Target Persisting Stem Cells in CML

NCT05701215 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Venetoclax

Sponsor

Thomas Ernst, PD Dr. med.

Collaborators

[object Object]
[object Object]